
MEI Pharma MEIP
MEI Pharma ROE Ratio | MEIP
Annual ROE Ratio MEI Pharma
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -170.94 | -94.18 | 53.84 | -129.95 | -103.03 | -82.89 | -61.22 | -35.09 | -79.41 | 5.25 | 28.53 | -54.68 | -60.07 | -32.08 | -163.58 | -377.98 | -106.98 | -73.49 | -75.05 | -100.31 | -80.85 | -38.87 | -37.22 | -51.12 | -1.38 |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 53.84 | -377.98 | -76.91 |
Quarterly ROE Ratio MEI Pharma
| 2027-Q1 | 2026-Q4 | 2026-Q3 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -42.47 | -70.73 | -108.36 | -69.91 | -109.78 | -114.5 | -95.47 | -22.94 | -12.12 | 75.05 | 114.85 | 0.62 | 14.9 | -67.26 | -105.03 | -104.65 | -90.94 | -124.05 | -117.69 | -72.28 | -79.32 | -39.15 | -55.1 | -62.28 | -31.93 | -71.94 | -23.29 | -53.53 | -98.06 | -70.31 | -108.65 | -92.25 | -62.63 | -45.66 | -8.16 | -8.16 | -13.47 | -23.82 | -55.35 | -45.43 | -41.05 | -37.86 | -36.51 | -33.99 | -43.42 | -59.07 | -70.69 | -82.87 | -73.19 | -64.99 | -54.05 | -42.05 | -78.51 | -153.22 | -183.25 | -228.93 | -222.5 | -180.13 | -226.77 | -263.05 | -48.05 | -85.9 | -89.86 |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 114.85 | -263.05 | -72.56 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - | ||
|
Lyra Therapeutics
LYRA
|
269.84 | - | - | $ 24.9 M | ||
|
Brickell Biotech
BBI
|
-57.34 | - | -5.38 % | $ 6.06 M | ||
|
Applied Therapeutics
APLT
|
-185.29 | - | - | $ 8.42 M | ||
|
ESSA Pharma
EPIX
|
-22.91 | - | - | $ 8.86 M | ||
|
Generation Bio Co.
GBIO
|
-152.74 | - | - | $ 344 M | ||
|
Clearside Biomedical
CLSD
|
88.41 | - | - | $ 25.3 M | ||
|
Merus N.V.
MRUS
|
-33.23 | - | - | $ 5.78 B | ||
|
RAPT Therapeutics
RAPT
|
-68.38 | - | - | $ 2.36 B | ||
|
Annexon
ANNX
|
-97.66 | $ 3.11 | -8.94 % | $ 482 M | ||
|
Acasti Pharma
ACST
|
-12.2 | - | 4.01 % | $ 150 M | ||
|
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | ||
|
Galapagos NV
GLPG
|
9.92 | - | - | $ 1.83 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
-5.66 | - | -4.36 % | $ 27 M | ||
|
Avenue Therapeutics
ATXI
|
-158.79 | - | -52.27 % | $ 4.45 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
-65.32 | $ 4.63 | 21.05 % | $ 20 M | ||
|
Achieve Life Sciences
ACHV
|
-253.96 | $ 6.78 | 0.89 % | $ 296 M | ||
|
Leap Therapeutics
LPTX
|
3.26 | - | 368.57 % | $ 41.9 M | ||
|
Lumos Pharma
LUMO
|
-124.64 | - | - | $ 35.3 M | ||
|
Gamida Cell Ltd.
GMDA
|
-73.63 | - | -18.25 % | $ 5.04 M | ||
|
Axcella Health
AXLA
|
-1949.71 | - | -16.42 % | $ 249 M | ||
|
Metacrine
MTCR
|
-108.46 | - | - | $ 24.2 M | ||
|
Zealand Pharma A/S
ZEAL
|
-109.74 | - | 0.52 % | $ 821 M | ||
|
Myovant Sciences Ltd.
MYOV
|
43.5 | - | -0.04 % | $ 2.62 B | ||
|
Bellerophon Therapeutics
BLPH
|
-782.6 | - | -74.18 % | $ 955 K | ||
|
Idera Pharmaceuticals
IDRA
|
-197.53 | - | -23.04 % | $ 26.6 M | ||
|
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
-84.78 | - | - | $ 69.7 B | ||
|
Atreca
BCEL
|
-123.92 | - | -11.76 % | $ 5.79 M | ||
|
Guardion Health Sciences
GHSI
|
1.94 | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
6.42 | - | - | $ 109 M | ||
|
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | ||
|
ImmunoGen
IMGN
|
-143.06 | - | - | $ 7.92 B | ||
|
Vascular Biogenics Ltd.
VBLT
|
-74.53 | - | -8.77 % | $ 12.4 M | ||
|
Cidara Therapeutics
CDTX
|
-103.99 | - | - | $ 1.41 B | ||
|
Iterum Therapeutics
ITRM
|
607.06 | - | - | $ 591 K | ||
|
Virpax Pharmaceuticals
VRPX
|
1320.61 | - | -45.12 % | $ 2.85 M | ||
|
Navidea Biopharmaceuticals
NAVB
|
179.91 | - | -2.99 % | $ 2.47 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
115.97 | - | - | $ 23.9 M | ||
|
OncoSec Medical Incorporated
ONCS
|
-558.64 | - | 31.87 % | $ 1.61 M | ||
|
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | ||
|
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | ||
|
bluebird bio
BLUE
|
763.35 | - | - | $ 546 M | ||
|
Landos Biopharma
LABP
|
-69.0 | - | 0.58 % | $ 144 M | ||
|
CASI Pharmaceuticals
CASI
|
-92.01 | - | - | $ 35.4 M | ||
|
ContraFect Corporation
CFRX
|
549.72 | - | -5.16 % | $ 5.39 M | ||
|
Sigilon Therapeutics
SGTX
|
-111.29 | - | - | $ 728 M |